Last $135.45 USD
Change Today -0.77 / -0.57%
Volume 1.1M
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILMN) Snapshot

Open
$136.93
Previous Close
$136.22
Day High
$138.33
Day Low
$133.66
52 Week High
03/4/14 - $183.30
52 Week Low
04/22/13 - $54.84
Market Cap
17.4B
Average Volume 10 Days
2.2M
EPS TTM
$2.03
Shares Outstanding
128.4M
EX-Date
--
P/E TM
66.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for ILLUMINA INC (ILMN)

illumina inc (ILMN) Details

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology are designed to meet the various demands of a range of sequencing applications; and array platforms consist of HiScan and iScan systems that are array scanners, which support the imaging of array-based genetic analysis products. It also offers various sample preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping and whole genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,000 Employees
Last Reported Date: 02/18/14
Founded in 1998

illumina inc (ILMN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.1M
President and Director
Total Annual Compensation: $153.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $447.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.1K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $449.6K
Compensation as of Fiscal Year 2013.

illumina inc (ILMN) Key Developments

Illumina, Inc. Announces New Products to Support Oncology Clinical Research and Discovery

Illumina Inc. announced new products that can be applied directly to the discovery and translation of genomic variation in blood and tissue associated with cancer. The following products complement the company's existing NGS and array portfolio and support efficient and streamlined workflows for cancer research and other applications using Illumina's NGS sequencers, including the newly launched NextSeq(TM) 500 sequencing system. TruSeq(R) RNA Access Library Prep Kits offer a reproducible, economical solution for analyzing RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tissues, and other low-quality samples. Starting with as little as 10 ng total RNA, the kits deliver the discovery power of RNA sequencing at a reduced cost by focusing on the coding regions of the transcriptome. The kits will begin shipping this month. In addition, the kits will be available on the NeoPrepTM Library Prep System in 2H 2014. TruSight(TM) Myeloid Sequencing Panel uses expert-curated content to offer accurate, efficient, and cost-effective identification of somatic mutations in myeloid malignancies. It provides an assessment of 54 critical genes, including tumor suppressor genes and hotspots in oncogenes. This fully integrated DNA-to-data solution offers a streamlined workflow and automated data analysis with somatic variant calling. New BaseSpace(R) Core Apps offer informatics support for the cancer market. The TopHat and Cufflinks Apps, as well as the RNA Express App, are designed to support transcriptome data analysis, including detection of fusion genes critical in cancer research. A Tumor Normal App delivers somatic variant calling of tumor and matched normal whole genome data sets based on the accurate Strelka method. In addition, Illumina is developing apps to analyze data from Illumina's TruSight Tumor Sequencing Panel and TruSeq Amplicon - Cancer Panel, as well as an exome version of the Tumor Normal App that delivers variants based on Nextera(R) Rapid Capture Enrichment data. The RNA-Seq and Tumor Normal Apps will be available early this month in BaseSpace, and the others will be available later in 2014.

Illumina Inc. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-05-2014 08:40 AM

Illumina Inc. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-05-2014 08:40 AM. Venue: Marriott Copley Place Hotel, Boston, Massachusetts, United States.

Illumina Inc. Presents at Morgan Stanley Technology, Media and Telecom Conference, Mar-06-2014 09:20 AM

Illumina Inc. Presents at Morgan Stanley Technology, Media and Telecom Conference, Mar-06-2014 09:20 AM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States. Speakers: Jason T. Flatley, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN:US $135.45 USD -0.77

ILMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $54.65 USD +0.97
Avago Technologies Ltd $60.89 USD +1.58
PerkinElmer Inc $44.27 USD +0.08
QIAGEN NV €14.80 EUR -0.043
Waters Corp $111.15 USD +1.33
View Industry Companies
 

Industry Analysis

ILMN

Industry Average

Valuation ILMN Industry Range
Price/Earnings 100.0x
Price/Sales 12.1x
Price/Book 11.3x
Price/Cash Flow 109.4x
TEV/Sales 10.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.